Dr. McGregor on unmet needs in metastatic renal cell carcinoma
Bradley McGregor, MD, explains how despite major advances in metastatic renal cell carcinoma, there are still patients who do not respond or maintain their initial response to the novel treatment option. Therefore, McGregor, says there remains a need for novel treatment targets and therapies in this space. McGregor is clinical director, Lank Center for Genitourinary Oncology, senior physician, instructor in Medicine, Harvard Medical School, Dana-Farber Cancer Institute.
Adding nivolumab to low-dose tivozanib does not improve PFS in renal cell carcinoma
July 19th 2024"While the addition of an ICI to low dose FOTIVDA did not improve PFS outcomes after prior ICI, we consider the control arm data an important, evidence-based and clinically meaningful contribution to the oncology community treating relapsed or refractory advanced RCC following front-line ICI combinations," says Michael P. Bailey.
Live bacterial supplementation may improve TKI-based treatment efficacy in kidney cancer
June 30th 2024CBM588 could be exciting in cancer treatment because of its potential to enhance the efficacy of immune checkpoint inhibitor-based treatment, improve patient outcomes, and modulate the gut microbiota in beneficial ways,” says Sumanta Pal, MD.
Pembrolizumab/lenvatinib labels updated to include KEYNOTE-B61 data in non-ccRCC
June 28th 2024"The addition of efficacy data from the KEYNOTE-B61 trial reinforces the important role of KEYTRUDA plus LENVIMA as a frontline treatment option for adult patients with advanced RCC regardless of histology," says Takashi Owa, PhD.
